Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
Allogeneic stem cell transplantation
Graft versus leukemia effect
Primary central nervous system lymphoma
Journal
Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
06
09
2017
revised:
12
01
2018
accepted:
20
02
2018
pubmed:
22
3
2018
medline:
10
5
2020
entrez:
22
3
2018
Statut:
ppublish
Résumé
Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.
Identifiants
pubmed: 29559300
pii: S1658-3876(18)30025-6
doi: 10.1016/j.hemonc.2018.02.001
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-225Informations de copyright
Copyright © 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.